Testosterone Therapy Medical Controversy: A History of the Debate and Its Resolution

Written by Keen Meds  ·  Reviewed by Licensed Clinical Providers  ·  March 1, 2026

Key Insight: The TOM Trial (NEJM 2010) stopped early after 23 cardiovascular events in the testosterone group vs. 5 in placebo — but the trial enrolled specifically high-risk elderly men with mobility limitations, a population not representative of typical TRT candidates.

From 2010 through 2023, testosterone therapy was at the center of one of the more sustained debates in clinical endocrinology. The controversy was not primarily about whether testosterone worked for men with hypogonadism -- most clinicians agreed that appropriately selected patients benefited -- but about whether testosterone therapy carried cardiovascular risk that outweighed those benefits.

The debate was complicated by the quality of the evidence on each side, the role of media coverage in shaping public perception, and the challenge of distinguishing correlation from causation in retrospective observational datasets. Understanding how this controversy developed and how it was ultimately resolved is useful for any patient who has encountered conflicting information about TRT safety.

The TOM Trial: The Study That Started the Modern Debate

The immediate origin of the modern TRT safety controversy is a trial published in the New England Journal of Medicine in 2010. The Testosterone in Older Men with Mobility Limitations (TOM) trial, led by Shehzad Basaria at the Boston Claude D. Pepper Older Americans Independence Center, was designed to examine whether testosterone therapy improved physical function in elderly men with limited mobility.

The trial enrolled 209 men aged 65 and older who had low or low-normal testosterone and functional limitations that affected their ability to walk or climb stairs. This was a highly specific population: older men with pre-existing mobility impairment and, by implication, a higher burden of underlying medical conditions than the general population of men who would typically seek testosterone therapy.

The trial was stopped early by its data safety monitoring board after a planned interim analysis revealed 23 cardiovascular-related adverse events in the testosterone group compared to 5 in the placebo group. The specific events included elevated blood pressure, irregular heart rate, and other cardiac findings. The disproportion triggered the early stopping rule, and the trial was terminated.

The TOM trial result entered the medical literature and the mainstream media as evidence that testosterone therapy was dangerous for older men. What received less prominent attention was the nature of the population enrolled. These were not typical candidates for TRT evaluation: they were frail elderly men with existing mobility limitations, a population with substantially elevated baseline cardiovascular risk. Applying TOM's findings broadly to otherwise healthy men in their 40s or 50s with low testosterone and typical symptoms was an extrapolation that the trial design did not support.

The Scientific Debate: Observational Data vs. Randomized Evidence

The years following TOM produced a significant volume of observational research on testosterone and cardiovascular outcomes, and that research produced inconsistent results.

Two studies published in 2013 and 2014 -- Vigen et al. in JAMA and Finkle et al. in PLoS ONE -- reported associations between testosterone prescriptions and adverse cardiovascular events using retrospective insurance claims and medical records data. Both generated intense media coverage and contributed to the FDA's 2015 decision to add a black box cardiovascular warning to all testosterone products.

The methodological criticisms of both studies were well-documented in the endocrinology literature. The Vigen study was found to have included women in the testosterone-treated cohort, an error that fundamentally compromised the analysis. The Finkle study compared men's event rates after filling a testosterone prescription to their own prior event rates, a design vulnerable to the "healthy initiator" bias in reverse -- men may seek TRT evaluation specifically during periods of worsening health, making the post-prescription period a misleading comparison baseline.

Meanwhile, other large observational datasets produced different signals. A study by Muraleedharan et al. (Heart, 2013) found lower all-cause mortality in testosterone-treated men with hypogonadism and type 2 diabetes compared to untreated men. An analysis by Shores et al. found reduced mortality in veterans who received testosterone. The heterogeneity of these observational findings reflected a consistent problem: observational studies of TRT were comparing treated patients to untreated patients who differed at baseline in ways that statistical adjustment could not fully correct.

The Saturation Model and the Theoretical Framework Debate

Concurrent with the epidemiological controversy, a theoretical debate was occurring in the endocrinology literature about how testosterone interacts with androgen-sensitive tissues.

Abraham Morgentaler, a urologist at Harvard and a prominent voice in TRT clinical research, had articulated what he called the saturation model. The saturation model proposed that androgen-sensitive tissues respond maximally to testosterone at relatively low concentrations, beyond which additional testosterone produces no further effect on those tissues. Under this model, raising testosterone from hypogonadal to normal-physiological levels would be expected to produce meaningful clinical benefits, while testosterone above the saturation threshold would have progressively diminishing marginal effects on androgen-responsive endpoints.

The saturation model had particular relevance to the debate over testosterone and prostate cancer, where the traditional view had been that testosterone stimulated prostate cancer growth, implying that TRT was dangerous in men at prostate cancer risk. Morgentaler's research suggested that the relationship between testosterone and prostate tissue was more consistent with the saturation model -- meaning that hypogonadal men were below the saturation threshold, and that normalizing their testosterone would not stimulate prostate growth to a greater degree than already existed in eugonadal men.

How the Scientific Community Tried to Resolve the Debate

The fragmented nature of the evidence base -- multiple small and medium-sized trials, large observational datasets with inconsistent findings, and a theoretical controversy over the underlying mechanism -- made consensus difficult. The endocrinology community's position throughout this period was that the safety question could only be definitively answered by a large, properly randomized, adequately powered clinical trial.

The Endocrine Society's 2018 clinical practice guidelines on testosterone therapy in men with hypogonadism, authored by Bhasin et al. in the Journal of Clinical Endocrinology and Metabolism, stated explicitly that the existing evidence was insufficient to establish whether testosterone therapy increases or decreases cardiovascular risk, and recommended against prescribing TRT to men with cardiovascular disease until cardiovascular safety had been established by randomized trial evidence.

The Resolution: TRAVERSE (2023)

The TRAVERSE trial, published in the New England Journal of Medicine in June 2023, was specifically designed to answer the cardiovascular safety question. It enrolled 5,246 men with hypogonadism and either established cardiovascular disease or elevated cardiovascular risk -- precisely the population in whom the safety concern was most acute -- and randomized them to testosterone or placebo for a median follow-up of approximately 3.2 years.

The primary outcome was non-inferiority for MACE (major adverse cardiovascular events). The hazard ratio was 0.96, with a 95% confidence interval of 0.83 to 1.12. Non-inferiority was confirmed. Testosterone therapy, in the highest-risk population for cardiovascular events among men with hypogonadism, did not increase the rate of heart attacks, strokes, or cardiovascular death compared to placebo.

The FDA cited TRAVERSE as the primary evidence basis for removing the cardiovascular black box warning from testosterone products in March 2025. That action marked the formal regulatory resolution of a debate that had lasted fifteen years.

What Patients Should Take Away from This History

The TRT safety controversy of 2010 to 2023 illustrates how medical knowledge develops when evidence is incomplete and when observational data cannot resolve questions that only randomized trials can answer. During this period, patients received conflicting information from different physicians, from media coverage, and from the product labeling required by FDA.

The resolution of that controversy is instructive. The observational signals from Vigen and Finkle did not withstand the scrutiny of randomized trial evidence. The TOM trial's findings applied to a population not representative of most TRT candidates. The TRAVERSE trial, conducted in a high-risk population where the question mattered most, found no increase in major cardiovascular events.

For patients evaluating testosterone therapy today, the cardiovascular safety debate has been answered by the highest standard of evidence available in clinical medicine.

Understanding Your Testosterone Today

The decade-long medical controversy over testosterone therapy has been resolved by rigorous randomized trial evidence. The question of cardiovascular safety is no longer the central uncertainty it was from 2010 to 2023. What remains essential is appropriate clinical evaluation: confirming that testosterone is genuinely low through validated lab testing, documenting relevant symptoms, and ruling out contraindications.

Keen Meds connects you with licensed clinical providers for a telehealth evaluation and lab review. If your testosterone is clinically low, you may qualify for a prescription for Testosterone Spray Rx -- a needle-free transdermal testosterone program.